Company Filing History:
Years Active: 2021
Title: Innovations by Hyung Suk Jang in Ischemic-Reperfusion Injury Treatment
Introduction
Hyung Suk Jang is an accomplished inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of ischemic-reperfusion injury. His innovative approach utilizes bile acids to enhance therapeutic outcomes in this critical area of medical research.
Latest Patents
Hyung Suk Jang holds a patent for a pharmaceutical composition aimed at preventing or treating ischemic-reperfusion injury. The patent, titled "Pharmaceutical composition for preventing or treating ischemic-reperfusion injury comprising bile acids," describes a composition that increases intranuclear beta-catenin levels and interferes with the opening of the mitochondrial permeability transition pore (mPTP). This invention has demonstrated excellent effects in animal models, alleviating tissue injury and reducing the size of infarcts, making it a promising candidate for clinical applications.
Career Highlights
Throughout his career, Hyung Suk Jang has worked with notable organizations, including the Samsung Life Public Welfare Foundation and Solsion Biomedical Inc. His work has focused on advancing medical treatments and improving patient outcomes through innovative pharmaceutical solutions.
Collaborations
Hyung Suk Jang has collaborated with esteemed colleagues in his field, including Hyeon Cheol Gwon and Dong Youn Lee. These partnerships have contributed to the development and refinement of his groundbreaking research.
Conclusion
Hyung Suk Jang's contributions to the field of pharmaceuticals, particularly in the treatment of ischemic-reperfusion injury, highlight his innovative spirit and dedication to improving healthcare. His work continues to pave the way for advancements in medical treatments.